|Bid||22.88 x 2900|
|Ask||22.91 x 4000|
|Day's Range||22.47 - 22.99|
|52 Week Range||13.00 - 23.58|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||44.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Joining me on the call today to discuss our results and response to the coronavirus global pandemic is Chief Executive Officer, Mark Benjamin; and Chief Financial Officer, Dan Tempesta. During the Q&A portion of the call, we will be joined by Rob Dahdah, Chief Revenue Officer; Robert Weideman, Executive Vice President of Enterprise; and Pete Durlach, Senior Vice President of Healthcare.
Nuance Communications (NUAN) delivered earnings and revenue surprises of 23.53% and 4.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nuance Communications (NUAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RGA Investment Advisors, LLC is an independent investment management firm based in New York. Jason Gilbert is the firm’s founder and managing partner. Recently, RGA Investment Advisors released its Q1 2020 Investor Letter – a copy of which can be downloaded here. In the said letter, Jason Gilbert highlighted that the firm bought Nuance Communications […]
Does the April share price for Nuance Communications, Inc. (NASDAQ:NUAN) reflect what it's really worth? Today, we...
Moody's Investors Service ("Moody's") affirmed Cerence Inc.'s ("Cerence") B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating (PDR) and changed the outlook to negative from positive. Moody's also affirmed the B2 ratings on the company's senior secured bank credit facilities and downgraded the Speculative Grade Liquidity Rating to SGL-2 from SGL-1.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Amidst all the uncertainty gripping the markets, right now, one thing remains constant: Volatility.The market pendulum is currently swinging wildly from one extreme to the other. However, in a recent note to clients, Wedbush analyst Daniel Ives notes that even in times of uncertainty, fundamentals remain key.“Our investing philosophy in times of crisis is to do a bottoms up analysis and stress test the models of our top tech names/themes vs. a sensitivity in valuations. If stocks stick out with a green light based on this exercise and framework, we hand hold investors to buy these dips through this volatility, own the names for the other side of this panic, and see the forest through the trees on the fundamental drivers for the next decade in tech” Ives said.With the help of TipRanks’ Stock Screener we got the low down on 3 tech names Ives believes 'stand out' at current levels. Digging further down, it appears all three currently boast a Strong Buy consensus rating from the Street. Let’s check them out.Varonis Systems (VRNS)One of the sectors Ives is most bullish on long-term is that of cyber security. Varonis is a pioneer in data security and analytics, and its offerings include everything from securing business data, systems management, data environments and file activity tracking.Despite a 15% drop year-to-date, Varonis posted gains of 52% last year, following a series of impressive earnings reports. Ives believes there’s more to come and argues the “the results speak for themselves.”While in its latest quarterly statement, the company posted modest beats on both top and bottom line, the all important ARR (annual recurring revenue) is where Varonis displayed its most impressive figures, the metric increasing by 62% year-over-year, handily above Street expectations.Additionally, with Varonis currently transitioning to a subscription based model over perpetual licenses, the Street had high expectations, and was looking for subscriptions to be over 75% of total license revenue. Varonis beat the figure by posting an “eye popping” 82% subscription mix.Ives said, “In the numerous software business model transitions we have seen play out over the past decade, we can never remember seeing a company so quickly ramp subscription revenues in the course of a few quarters, which speaks to a massive success story so far for the company (and its investors)... We believe Varonis’ platform offers a broad range of features and unique functionalities that differentiates it from traditional data security offerings and continues to be in the sweet spot of purchasing cycles which is starting to resonate with customers in our opinion heading into the next 12 to 18 months.”Ives keeps his Outperform rating intact along with a $105 price target, which implies a possible upside of 94% in the coming months. (To watch Ives’ track record, click here)The Street is on the Wedbush analyst’s side. 10 Buys and 2 Hold ratings given to the data security specialist over the last three months add up to a Strong Buy consensus rating. At $100.27, the upside potential comes in at a healthy 85%. (See Varonis stock analysis on TipRanks)J2 Global Communications (JCOM)Cloud computing is another sector Ives sees as expanding in the new decade, which brings us nicely to J2 Global. The Los Angeles based company provides internet services through two different segments: business cloud services and digital media.J2’s share price is down by 18.5% year-to-date, but it’s worth bearing in mind that it notched an all-time-high on January 21. If things pan out as Ives forecasts, J2 Global will be reaching new heights in the year ahead.Since launching its digital division in 2012 with the purchase of digital publisher Ziff Davis, J2 has been aggressive on the acquisition front, and the company now boasts a portfolio of over 40 brands, including PCMag, Mashable, and Everyday Health, amongst others.Ives argues JCOM has been a “misunderstood story” by the Street. In the past, seen by many investors as a legacy fax player (e-Fax) and serial M&A machine, with low growth prospects and high margins. But the analyst maintains that with aggressive M&A, a disciplined cash flow machine, and a number of strategic initiatives possibly to come, JCOM could see further “multiple expansion and growth.”Ives said, “We reiterate our belief that the merits of this story are gaining further steam under the leadership of CEO Vivek Shah as his digital media strategy continues to take hold on the heels of stronger subscription revenue and a continued improvement in display advertising. In our opinion the underlying acquisitive growth ($550 million convert adds to M&A war chest) strategy of diversifying its core services beyond fax into cloud and media is the key ingredient in its formula for success and will continue to be the linchpin going forward as evidenced again this quarter.”Ives puts a $110 price target on JCOM to go along with his Outperform rating. Should the target be met over the next 12 months, investors stand to pocket a 67% gain.What does the Street have in mind for the internet services provider? J2’s Strong Buy consensus rating breaks down into 6 Buy ratings and 2 Holds. The average price target comes in at $109.14, indicating potential upside of 67%. (See JCOM's price targets and analyst ratings on TipRanks)Nuance Communications (NUAN)Staying in cloud based services, we come to Nuance Communications, a company providing speech recognition software and artificial intelligence solutions. Despite the overall volatility in the markets, Nuance has been holding up well, among the few names to stay in the green in 2020.The company’s latest quarterly statement was a strong one with beats across the board.Revenue of $418.3 million beat the estimate by $12 million, while EPS of $0.27 beat the Street’s call by $0.03. Nuance’s all important cloud-based speech platform for physicians, Dragon Medical Cloud saw 51% revenue growth from the same period last year.Nuance has also formed a partnership with Microsoft. In October the two announced an initiative to help reduce burnout among clinicians with the delivery of ambient clinical intelligence (ACI) technologies. According to the company’s press release these will “power the exam room of the future where clinical documentation writes itself.”Ives believes that following a bumpy ride in the last decade, new CEO Mark Benjamin has engineered one of the more “impressive strategic and fundamental turnarounds” he has seen in decades.Ives said, “We believe the underlying visibility increasing in the model from the key healthcare initiatives along with healthy profitability/cash flow lay the groundwork for a strategic organic growth reacceleration story over the coming years that should result in a further re-rating of the stock as the Street recognizes the "new and improved Nuance" story.”Ives reiterates an Outperform on Nuance along with a $27 price target. Investors stand to take home a 82% gain, should the figure be met over the next 12 months.Out on the Street, Nuance’s Strong Buy consensus rating is based solely on Buys - 5, in fact. The average price target is $23.80 and suggests the analysts see a further 59% added to the share price over the coming year. (See Nuance stock analysis at TipRanks)
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Nuance Communications, Inc. New York, March 05, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Nuance Communications, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Despite the fear and panic generated by the coronavirus outbreak, tech investors should take the long view, urged Wedbush analyst Dan Ives in a note on Sunday. Such times of extreme anxiety and panic represent "golden buying opportunities" for the stocks and themes that wind up winning in the the long-term, according to Ives. "Our long standing view during this last decade… is that we are in the midst of a unprecedented tech bull market with themes such as the enterprise move to cloud computing, a transformational 5G super cycle, EV auto demand inflection, streaming cord cutting paradigm shift, and cyber security all representing some of the major game changing trends poised to change the consumer and enterprise landscape for the next decade," Ives wrote on Sunday.
Nuance Communications (NUAN) delivered earnings and revenue surprises of 17.39% and 3.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Microsoft's (MSFT) second-quarter fiscal 2020 results are likely to reflect momentum in Azure, robust Office 365 adoption, impressive LinkedIn growth and higher Surface devices revenues.
Microsoft's (MSFT) fiscal second-quarter results are likely to reflect gains from strength in Azure and robust adoption of business productivity offerings.
Piedmont Healthcare picked the replacement for former chief health information officer Robert Budman, who is now chief medical information officer with Nuance Communications.
Today we'll look at Nuance Communications, Inc. (NASDAQ:NUAN) and reflect on its potential as an investment. In...
As we round the corner on the current decade, investors are laser focused on the market, trying to determine what’s in the cards for stocks as we make our way into 2020. However, the U.S. presidential election as well as the slowing pace of buybacks and economic growth in the U.S. add up to expected volatility in the year ahead.Against this backdrop, investing titan Howard Marks believes the economy isn’t in a bubble, but he advises that investors take some caution. “The economic expansion and the bull market are old. Valuations are above average. There’s a lot of uncertainty in the world and it strikes me that one should not have as much risk as one did three years ago or six years ago,” Marks told CNBC.Bearing this in mind, we set out to find the names that remain poised to outperform the market given the uncertainty hanging over our heads as we ring in the new year. Looking to the analysts for guidance, we zeroed in on 3 stocks with stellar long-term growth prospects. After running the names through TipRanks’ Stock Screener tool, it appears that each has the support of Wall Street analysts as well, earning a “Strong Buy” consensus rating.Flexion Therapeutics (FLXN) Flexion is working to develop better treatments for patients with musculoskeletal conditions including osteoarthritis (OA), a condition that affects over 30 million people in the U.S. Even with shares already up 84% year-to-date, some members of the Street are betting that FLXN’s growth story is still heating up.Part of the optimism surrounding FLXN is based on the strong performance of its Zilretta drug. In its most recent quarter, the company was able to post a 15% revenue beat. On top of this, its new rebate program caused the therapy’s sales to increase 29% quarter-over-quarter to reach $21.8 million, zipping past the $19 million consensus estimate. While Wells Fargo analyst Jacob Hughes notes that the bears will say there has been a “collapse” in pricing, he doesn’t believe that this is the case. “We believe revenues were actually understated this quarter because of some distributor destocking. Based on the Q3 sales momentum, we think Q4 consensus numbers are too low and we raise our revenue estimates,” Hughes explained. To this end, the analyst decided to stay with the bulls, reiterating an Outperform rating alongside $26 price target. (To watch Hughes’ track record, click here)Meanwhile, Needham’s Serge Belanger focuses on the discontinuation of its Zilretta Phase 3 trial for hip OA pain as a result of a non-safety issue that wasn’t resolved. He argues that this should have a relatively limited impact on Zilretta’s market opportunity as there are less than 500,000 annual hip OA injections compared to 8 million for knee OA and 1 million for shoulder OA. It should also be noted that Belanger believes that there’s a strong likelihood that FLXN’s label change request to include repeat-dosing will be approved based on Phase 3b trial data. This led him to keep the Buy rating and $36 price target as is. At this target, shares could be in for a 67% gain in the twelve months ahead. (To watch Belanger’s track record, click here)How does the rest of the Street feel about FLXN? Based on the 5 Buys vs no Holds or Sells, the message is clear: the biopharma is a Strong Buy. In addition, the $29 average price target implies 32% upside potential from current levels. (See Flexion stock analysis on TipRanks) Nuance Communications (NUAN) This tech company uses conversational AI to revolutionize the way people interact with technology and each other. Its solutions are already being utilized throughout the healthcare, telecom, financial services and government sectors.Looking at its performance during its fiscal 2019 fourth quarter, there’s no question as to why several analysts are getting excited. Revenue and EPS exceeded the consensus estimates, with the healthcare segment seeing a 9% year-over-year revenue increase. While revenue for its enterprise segment did slow, Oppenheimer analyst Shaul Eyal expects this area to stabilize in full year 2020. Eyal adds, “We applaud NUAN's team for delivering another solid quarter while navigating a series of strategic initiatives to enhance operational efficiency and profitability. We view favorably NUAN's current focus on two simplified segments, the low growth yet predictable healthcare business and the faster growing enterprise business.” This prompted the five-star analyst to maintain his bullish call and $23 price target. (To watch Eyal’s track record, click here)Wedbush's Daniel Ives, echoing the view of Eyal, reiterated an the Outperform rating on NUAN alongside a $24 price target, which implies nearly 40% upside potential. (To watch Ives’ track record, click here)Ives noted, “We believe the underlying visibility increasing in the model from the key healthcare initiatives along with healthy profitability/ cash flow lay the groundwork for a strategic organic growth reacceleration story over the coming years that should result in a re-rating of the stock as the Street recognizes the ‘new and improved Nuance’ story.” In general, other Wall Street analysts are in agreement. 5 Buys and 1 Hold add up to a Strong Buy analyst consensus. Given the $21 average price target, shares could surge 18% in the coming twelve months. (See Nuance stock analysis on TipRanks)Lumentum Holdings (LITE) Last but not the least is Lumentum, which offers its customers a portfolio of innovative photonics solutions to accelerate the speed and scale of cloud, networking, 3D sensing and advanced manufacturing applications. Based on major trends in the optical space, some believe that LITE’s future looks bright.Citing LITE as a top pick, Rosenblatt Securities analyst Jun Zhang argues that significant catalysts are in store. The company could see substantial growth in fronthaul, midhaul and backhaul optical modules, lasers and ROADMs thanks to 5G and stand-alone network deployments. As LITE is the key supplier for 25G and 56G laser chipsets, it also stands to benefit from Google and Amazon’s 400G optical module deployments as the focus on higher end lasers could lead to gross margin improvement.Additionally, LITE is well-positioned to take advantage of the expanding augmented reality space. “We view LITE is the key beneficiary from growth in the AR market. We believe LITE has the best quality of VCSEL laser and we expect Huawei may use LITE again if Huawei tries to improve their 3D ToF solution for their flagship smartphones that support better AR experiences,” Zhang stated.Overall, the four-star analyst thinks that these catalysts imply the Street’s estimates are too conservative. To this end, he stayed with the Buy recommendation while raising the price target from $80 to $90. This new target conveys Zhang’s confidence in LITE’s ability to jump 29% in the next twelve months. (To watch Zhang’s track record, click here)Like Zhang, Wall Street has been impressed by LITE. With the ratio of Buys to Holds at 12 to 1, the word on the Street is that the stock is a Strong Buy. However, the $75.86 average price target indicates modest 3% upside potential. (See Lumentum stock analysis on TipRanks)
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
Nuance Communications Inc. was upgraded to a Buy by TheStreet's quantitative service. Regular readers of "Kamich's Korner" know that I often use the quantitative service to look for new investment ideas.